Adverse events associated with SARS-CoV-2 vaccination in patients with glomerular diseases and the potential risk of disease reactivation

Active immunization against SARS-CoV-2 has been a critical mitigation tool during the pandemic.1,S1,S2 Patients with glomerular diseases (GDs) are at risk for severe illness caused by SARS-CoV-2, due to impaired kidney function and long-standing immunosuppressive therapy. Therefore, vaccination is of high importance for these patients. However, multiple reports have described new onset or relapse of GDs following SARS-CoV-2 vaccination, although details of clinical characteristics of vaccine-associated GD recurrence are unknown.